Doximity (DOCS)
(Delayed Data from NYSE)
$39.32 USD
+1.10 (2.88%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $39.33 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.32 USD
+1.10 (2.88%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $39.33 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Zacks News
All You Need to Know About Doximity (DOCS) Rating Upgrade to Buy
by Zacks Equity Research
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ICLR vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. DOCS: Which Stock Is the Better Value Option?
Compared to Estimates, Doximity (DOCS) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Doximity (DOCS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Doximity (DOCS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix
by Zacks Equity Research
Medpace, Doximity and Biodesix have been highlighted in this Industry Outlook article.
Earnings Estimates Moving Higher for Doximity (DOCS): Time to Buy?
by Zacks Equity Research
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Medical Services Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend.
ICLR or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Doximity (DOCS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Doximity (DOCS) stock based on the movements in the options market lately.
MD or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. DOCS: Which Stock Is the Better Value Option?
Implied Volatility Surging for Doximity (DOCS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Doximity (DOCS) stock based on the movements in the options market lately.
Here's What Key Metrics Tell Us About Doximity (DOCS) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Doximity (DOCS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 26.67% and 1.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -3.45% and 3.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 9.09% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.
BLCO or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Doximity (DOCS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 17.65% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?